Brokerages predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will report sales of $27.79 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Tabula Rasa HealthCare’s earnings. The lowest sales estimate is $27.7 million and the highest is $27.96 million. The company is expected to issue its next quarterly earnings results on Monday, August 7th.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full year sales of $27.79 million for the current fiscal year, with estimates ranging from $116.9 million to $117.61 million. For the next financial year, analysts anticipate that the business will post sales of $142.59 million per share, with estimates ranging from $139.1 million to $146.04 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings data on Monday, May 1st. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.06 by $0.02. The business had revenue of $27.70 million for the quarter, compared to analyst estimates of $26 million. The firm’s quarterly revenue was up 37.1% on a year-over-year basis.
Several analysts recently issued reports on TRHC shares. Stifel Nicolaus upped their price objective on shares of Tabula Rasa HealthCare from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, March 14th. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a report on Friday, April 7th. Robert W. Baird set a $17.00 target price on shares of Tabula Rasa HealthCare and gave the company a “buy” rating in a report on Thursday, January 19th. Finally, Piper Jaffray Companies boosted their target price on shares of Tabula Rasa HealthCare from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Tuesday, March 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $16.75.
Tabula Rasa HealthCare (NASDAQ:TRHC) traded up 0.53% on Thursday, hitting $13.32. 51,076 shares of the company’s stock traded hands. The stock has a 50-day moving average of $13.28 and a 200-day moving average of $13.53. Tabula Rasa HealthCare has a one year low of $10.39 and a one year high of $16.85. The stock’s market cap is $229.34 million.
TRADEMARK VIOLATION WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/05/20/tabula-rasa-healthcare-inc-trhc-expected-to-announce-quarterly-sales-of-26-07-million-updated-updated.html.
Several institutional investors have recently modified their holdings of the company. DIAM Co. Ltd. bought a new position in shares of Tabula Rasa HealthCare during the third quarter valued at approximately $136,000. Bank of New York Mellon Corp bought a new position in shares of Tabula Rasa HealthCare during the first quarter valued at approximately $178,000. Laurion Capital Management LP bought a new position in shares of Tabula Rasa HealthCare during the third quarter valued at approximately $430,000. State Street Corp bought a new position in shares of Tabula Rasa HealthCare during the fourth quarter valued at approximately $611,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Tabula Rasa HealthCare during the fourth quarter valued at approximately $875,000. Hedge funds and other institutional investors own 23.79% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare Inc and related companies with MarketBeat.com's FREE daily email newsletter.